contact

Management & Scientific Team

Michael Mullan, M.B.B.S., Ph.D.
Chief Executive Officer & Chief Scientific Officer

Michael Mullan, M.B.B.S., Ph.D., is the chief executive officer and chief scientific officer for Archer Pharmaceuticals, Inc. in Sarasota, Florida.

Prior to relocating to Florida, Dr. Mullan resided in London, England, where he was a part of the team to identify the first-known genetic cause of Alzheimer’s disease. 

Dr. Mullan has more than 20 years of experience in the development of biotechnology and intellectual property. He is also an inventor on the patents covering the use of the original APP mutations and the co-inventor on 20 other patents.

Throughout his career, Dr. Mullan has received several major grants and contracts from both private and federal organizations to work on the causes and cures of Alzheimer’s disease.

Dr. Mullan is a physician and scientist trained at the Royal Free School of Medicine and St. Mary’s Hospital Medical School in London, England.

 

Fiona Crawford, Ph.D.
Chief Technical Officer & Associate Chief Scientific Officer

Fiona Crawford, Ph.D., is the chief technical officer and associate chief scientific officer for Archer Pharmaceuticals, Inc. in Sarasota, Florida.

Dr. Crawford is from Belfast, Northern Ireland, and her Ph.D. training was in London, England, where she was a part of the team that identified the first Alzheimer’s mutations.  Dr. Crawford has 20 years of experience in the field of research and development for Alzheimer’s disease and related disorders.

Throughout her career, Dr. Crawford has received and managed numerous grants and contracts for neuroscience research.

Dr. Crawford is a molecular biologist trained at the Queen’s University of Belfast in Northern Ireland, and St. Mary’s Hospital Medical School in London, England.

 

Jerry L. Smith, CPA
Chief Financial Officer

Jerry L. Smith, CPA is the chief financial officer for Archer Pharmaceuticals, Inc. Mr. Smith has more than 30 years of financial and operational experience serving both closely-held and publicly-traded corporations, as well as high-net-worth individuals.

Previously, Mr. Smith was the divisional chief financial officer for a NASDAQ-traded chemical manufacturer, where he worked closely with other management to achieve greater profitability. As a key financial management member of a NYSE-traded chemical company, he directed entity and management performance reporting, acquisitions and divestments, internal audit and manufacturing accounting.

Mr. Smith is an adjunct professor for Webster University, teaching graduate and undergraduate accounting. Mr. Smith is a member of the American Institute of Certified Public Accountants and the State Society, where he has served on various committees. He is also the chair of his city’s employees’ retirement plan and a member of the city’s finance committee.

Mr. Smith received his Master of Accountancy from the University of Missouri and his Bachelor of Science in Business Administration and Accounting from Southeast Missouri State University.

 

Steven Ford
Regulatory Consultant

Steven Ford is the regulatory consultant for Archer Pharmaceuticals, Inc. Dr. Ford is also the principal consultant for Prime-Strategix.

Dr. Ford has more than 20 years of experience in the biopharmaceutical industry, and has worked on several development teams to take four products from concept to marketing approval. Dr. Ford has filed more than 20 marketing applications and has covered development of drug delivery systems, novel designer proteins, monoclonal antibodies and cellular therapies, as well as medical device products.

Prior to Archer, Dr. Ford was the vice president of product development at Chimeric Therapies, Inc. He also worked at Amgen, Inc. in North America and Ethical Pharmaceuticals, Ltd. in the United Kingdom.

Dr. Ford received his Ph.D. in microbial biochemistry from the University of Southampton in England.

Lead Scientists

Ghania Ait-Ghezala, Ph.D.
Head of Molecular Biology

Dr. Ait-Ghezala leads the program that is focused on developing molecular and cell biology-based screening of small molecule inhibitors and modulators for gamma secretase activity.

Venkat Mathura, Ph.D.
Head of Bioinformatics and Cheminformatics

Dr. Mathura is responsible for virtual screening, computational drug design, in silico lead optimization and molecular modeling.

 

Daniel Paris, Ph.D.
Head of Research & Development

Dr. Paris leads a team of multidisciplinary scientists focused on identifying molecular targets and developing in vitro and in vivo screens for Alzheimer’s disease.  In addition, he is in charge of preclinical development and testing of the lead compounds in Archer’s pipeline.